NFKB1 and neoplasm: As previously reported, pictilisib is a potent inhibitor of osteoclast differentiation and bone resorption in vitro and effectively prevents tumor-mediated osteolytic lesions in vivo by inhibition of the PI3K–AKT–GSK3β and NF-κB pathways (36).